Results 51 to 60 of about 13,254 (218)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation [PDF]

International Journal of Hematology-Oncology and Stem Cell Research, 2005
Objective: To evaluate the potential advantages of imipenem/cilastatin in control of fever in neutro-penic HSCT recipients.Patients and Method: In this single-center study, 111 consecutive febrile episodes in 104 neutropenic HSCT recipients with a mean ...
C Kani, A Mousavi, M Iravani, K Alimoghaddam, B Bahar, M Jahani, A Ghavamzadeh   +6 more
doaj   +1 more source

Postpartum Necrotizing Myometritis

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT We present a case of postpartum necrotizing myometritis, a rare complication that often occurs following transcatheter arterial embolization for the treatment of postpartum hemorrhage, and its etiology is closely associated with uterine ischemia and bacterial infection.
Jiangyan Xie
wiley   +1 more source

Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection

Cureus
Mycobacterium abscessus is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit M. abscessus β-lactamase (BLAMab) and increase the activity of imipenem and amoxicillin.
Anastasios Vogiatzoglou, Maria Hadji Μitrova, Eleni Papadaki, Maria Sionidou, Anna Nikopoulou, Fanοurios Kontos, Dimitrios Papaventsis, A. Papavasileiou, K. Manika   +8 more
semanticscholar   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.

PLoS ONE, 2019
BACKGROUND:We demonstrated therapeutic nonequivalence of "bioequivalent" generics for meropenem, but there is no data with generics of other carbapenems.
Maria Agudelo, Carlos A Rodriguez, Andres F Zuluaga, Omar Vesga   +3 more
doaj   +1 more source

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

BMC Infectious Diseases, 2010
Background Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram ...
Chen Xiaoping, Quan Zhiwei, Yan Lunan, Li Rong, Bi Jianwei, Leng Xisheng, Wei Junming, Zhang Yingyuan, Wu Jufang, Chen Zhangjing, Yu Yunsong, Wu Zhiyong, Liu Dawei, Ma Xiaochun, Maroko Robert, Cooper Angel   +15 more
doaj   +1 more source

Remodeling the Inflammatory Microenvironment: Nanomaterial‐Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis

Small Science, Volume 6, Issue 3, March 2026.
Current treatments for severe lupus nephritis are limited by side effects due to poor drug targeting. This review explores how smart nanomaterials—like liposomes and biomimetic carriers—can precisely deliver drugs to overactive immune cells and the kidneys. These nanotherapeutics enhance efficacy, reduce toxicity, and enable combination strategies. The
Cheng Zhou, Jiayi Li, Jian Zhang, Haifeng Wang, Haitao Lu, Shunlai Shang, Wenge Li   +6 more
wiley   +1 more source

Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery

International Journal of Molecular Sciences, 2021
Mesoporous silica nanomaterials have emerged as promising vehicles in controlled drug delivery systems due to their ability to selectively transport, protect, and release pharmaceuticals in a controlled and sustained manner.
Samuel Martinez-Erro, F. Navas, Eva Romaní-Cubells, Paloma Fernández-García, V. Morales, R. Sanz, R. A. García-Muñoz   +6 more
semanticscholar   +1 more source

Empiric antibiotic therapy in the treatment of community-acquired pneumonia in a general hospital in Saudi Arabia

Journal of Global Infectious Diseases, 2019
Background: Guideline-based empiric antimicrobial therapy is recommended for the treatment of community-acquired pneumonia (CAP). In this study, we evaluate the pattern of empiric antibiotics of CAP patients. Materials and Methods: Patients with CAP were
Jaffar A Al-Tawfiq, Hisham Momattin, Kareem Hinedi   +2 more
doaj   +1 more source

Peritoneal Dialysis‐Related Mycobacterium fortuitum Exit‐Site/Tunnel Infection in a Pediatric Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT In patients in peritoneal dialysis (PD) who develop exit site and/or catheter tunnel infections, expeditious identification of the causative organism and early implementation of treatment are important to ensure good outcomes. Among the many causative organisms, the diagnosis of Mycobacterium fortuitum is particularly challenging, with its ...
Rina Takahashi, Hiroshi Tamura, Keishiro Furuie, Hiroko Nagata, Shohei Kuraoka   +4 more
wiley   +1 more source